Health Biotech Limited WHO-GMP
Health Biotech Limited
Health Biotech Limited Health Biotech Limited
Health Biotech Limited Health Biotech Limited



Health Biotech Limited
Home - Products - Oncology(Anti-Cancer-Injectables) - Methotrexate Injection

Methotrexate Injection

Category: Anticancer
Each vial contains:-
Category: Anticancer
Each vial contains:-
: Each ML contains: Methotrexate(anhydrous) USP------------7.5mg/25mg, 50 mg
Specifications
: Methotrexate is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Between 7.5 to 9.0.

Composition : Each ml contains:
Methotrexate(anhydrous) USP------------7.5mg/25mg, 50 mg
q.s.
Indications : Methotrexate is indicated in the treatment of Gestational Choriocarcinoma, Chorioadenoma Destruens and Hydatidiform mole. In acute lymphocytic leukemia, Methotrexate is indicated in the prophylaxis of Meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of Meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, Epidermoid cancers of the head and neck, advanced mycosis fungoides , and lung cancer, particularly Squamous cell and small cell types.
Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis
Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis.
Contraindications : Methotrexate can cause fetal death or teratogenic effects when administered to a pregnant woman. Patients with psoriasis or rheumatoid arthritis with alcoholism, alcoholic liver disease or other chronic liver disease should not receive Methotrexate. Patients with psoriasis or rheumatoid arthritis who have overt or laboratory evidence of immunodeficiency syndromes should not receive Methotrexate.
Patients with psoriasis or rheumatoid arthritis who have preexisting blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia, should not receive methotrexate.
Patients with a known hypersensitivity to methotrexate should not receive the drug..
Pharmacological action: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, Methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of Methotrexate..

Storage Store at room temperature 15° to 30°C (59° to 86°F),
Purity :Not less than 99.5%.
» Get an Instant Quote

Methotrexate Injection
Ask for Price
Health Biotech Limited
Our Products
Oncology(Anti-Cancer-Injectables)  |   Pre-Filled Syringes  |   Anti-Infectives Injections   |   Liquid Ampoules / Vials  |   Biological Injections
Cardiovascular Injections  |   Neurology  |   Other Injectables  |   Hormones  |   Eye/ Ear/ Nasal Drops  |   Liquid Syrups, Dry Syrups & Redi-Mix Syrups  |   Pharmaceutical Capsules  |   Pharmaceutical Tablets  |   Tablets and Capsule  |   Green Tea Fat Burner


Clicky Web Analytics

Looking for Product Name ?